Marta Garcia de Herreros
Overview
Explore the profile of Marta Garcia de Herreros including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
64
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Pardo M, Garcia de Herreros M, Laguna J, Gorria T, Lage Y, Gomez A, et al.
Clin Lung Cancer
. 2025 Mar;
PMID: 40064572
No abstract available.
2.
Garcia Adrian S, Perez C, Carmona-Bayonas A, Ortega Moran L, Rubio Perez J, Del Prado P, et al.
Haematologica
. 2024 Dec;
PMID: 39665199
Patients with cancer present a higher risk of rethrombosis and bleeding secondary to anticoagulant treatment than individuals without cancer. Given the lack of specific clinical trials, the decision regarding the...
3.
Garcia de Herreros M, Jimenez N, Rodriguez-Carunchio L, Lillo E, Marin-Aguilera M, Ferrer-Mileo L, et al.
Eur Urol Open Sci
. 2024 Nov;
70:86-90.
PMID: 39502104
Patient Summary: We looked at outcomes for patients with metastatic hormone-sensitive prostate cancer treated with hormone therapies. We found that patients with low expression of two out of three tumor...
4.
Segui E, Torres J, Auclin E, Casadevall D, Peiro Carmona S, Aguilar-Company J, et al.
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272832
Purpose: Inflammation and neutrophils play a central role in both COVID-19 disease and cancer. We aimed to assess the impact of pre-existing tumor-related inflammation on COVID-19 outcomes in patients with...
5.
Garcia de Herreros M, Laguna J, Padrosa J, Barreto T, Chicote M, Font C, et al.
Diagnostics (Basel)
. 2024 Apr;
14(7).
PMID: 38611643
Background: Despite the increasing number of ICU admissions among patients with solid tumours, there is a lack of tools with which to identify patients who may benefit from critical support....
6.
Jimenez N, Garcia de Herreros M, Reig O, Marin-Aguilera M, Aversa C, Ferrer-Mileo L, et al.
Eur Urol Oncol
. 2024 Mar;
7(4):954-964.
PMID: 38429210
Background: Androgen deprivation therapy (ADT) with docetaxel (D) and/or antiandrogen receptor therapies (ARTs) are the standard therapies in metastatic hormone-sensitive prostate cancer (mHSPC). Alterations in the tumor suppressor genes (TSGs)...
7.
Grafia I, Chumbita M, Segui E, Cardozo C, Laguna J, Garcia de Herreros M, et al.
Microbiol Spectr
. 2023 Aug;
:e0214223.
PMID: 37610217
We aimed to describe the characteristics and outcomes of biliary source bloodstream infections (BSIs) in oncological patients. Secondarily, we analyzed risk factors for recurrent BSI episodes. All episodes of biliary...
8.
Jimenez N, Reig O, Marin-Aguilera M, Aversa C, Ferrer-Mileo L, Font A, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230681
(1) Background: Androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts...
9.
Pedrosa L, Foguet C, Oliveres H, Archilla I, Garcia de Herreros M, Rodriguez A, et al.
Front Immunol
. 2022 Sep;
13:926304.
PMID: 36119118
Existing immune signatures and tumor mutational burden have only modest predictive capacity for the efficacy of immune check point inhibitors. In this study, we developed an immune-metabolic signature suitable for...
10.
Garcia de Herreros M, Esposito F, Sauri T, Font C
J Oncol Pharm Pract
. 2022 Jul;
29(3):738-745.
PMID: 35876362
Introduction: Thrombotic microangiopathy (TMA) is an uncommon complication that may occur in cancer patients usually as an expression of cancer-associated coagulopathy or due to drug-related toxicity. The clinical spectrum of...